Literature DB >> 20042590

Critical protective role for MCP-1 in pneumonic Burkholderia mallei infection.

Andrew Goodyear1, Abby Jones, Ryan Troyer, Helle Bielefeldt-Ohmann, Steven Dow.   

Abstract

Burkholderia mallei is a gram-negative bacterial pathogen of domestic equidae and humans that can cause severe, rapidly life-threatening pneumonic infections. Little is known regarding the role of chemokines and early cellular immune responses in protective immunity to pulmonary infection with B. mallei. Although the role of MCP-1 in gram-positive bacterial infections has been previously investigated, the role of MCP-1 in immunity to acute pneumonia caused by gram-negative bacteria, such as B. mallei, has not been assessed. In a mouse model of pneumonic B. mallei infection, we found that both MCP-1(-/-) mice and CCR2(-/-) mice were extremely susceptible to pulmonary infection with B. mallei, compared with wild-type (WT) C57Bl/6 mice. Bacterial burden and organ lesions were significantly increased in CCR2(-/-) mice, compared with WT animals, following B. mallei challenge. Monocyte and dendritic cell recruitment into the lungs of CCR2(-/-) mice was significantly reduced in comparison with that in WT mice following B. mallei infection, whereas neutrophil recruitment was actually increased. Depletion of monocytes and macrophages prior to infection also greatly raised the susceptibility of WT mice to infection. Production of IL-12 and IFN-gamma in the lungs after B. mallei infection was significantly impaired in both MCP-1(-/-) and CCR2(-/-) mice, whereas treatment of CCR2(-/-) mice with rIFN-gamma restored protection against lethal challenge with B. mallei. Thus, we conclude that MCP-1 plays a key role in regulating cellular immunity and IFN-gamma production following pneumonic infection with B. mallei and therefore may also figure importantly in other gram-negative pneumonias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042590      PMCID: PMC2878842          DOI: 10.4049/jimmunol.0900411

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis.

Authors:  W Peters; H M Scott; H F Chambers; J L Flynn; I F Charo; J D Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

2.  Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs.

Authors:  Mark Mathes; Michael Jordan; Steven Dow
Journal:  Exp Hematol       Date:  2006-10       Impact factor: 3.084

3.  Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression.

Authors:  Holly M Scott; JoAnne L Flynn
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

4.  A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses.

Authors:  W Peters; M Dupuis; I F Charo
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

5.  Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity.

Authors:  Tim R Traynor; Amy C Herring; Martin E Dorf; William A Kuziel; Galen B Toews; Gary B Huffnagle
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

6.  TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection.

Authors:  Natalya V Serbina; Thais P Salazar-Mather; Christine A Biron; William A Kuziel; Eric G Pamer
Journal:  Immunity       Date:  2003-07       Impact factor: 31.745

7.  Role of chemokine ligand 2 in the protective response to early murine pulmonary tuberculosis.

Authors:  Andre Kipnis; Randall J Basaraba; Ian M Orme; Andrea M Cooper
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

8.  Lymphocyte activation in the lungs of SP-D null mice.

Authors:  James H Fisher; Jaque Larson; Carlyne Cool; Steve W Dow
Journal:  Am J Respir Cell Mol Biol       Date:  2002-07       Impact factor: 6.914

9.  Genome sequence alterations detected upon passage of Burkholderia mallei ATCC 23344 in culture and in mammalian hosts.

Authors:  Claudia M Romero; David DeShazer; Tamara Feldblyum; Jacques Ravel; Donald Woods; H Stanley Kim; Yan Yu; Catherine M Ronning; William C Nierman
Journal:  BMC Genomics       Date:  2006-09-05       Impact factor: 3.969

10.  CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained neutrophilic inflammation.

Authors:  N Sato; S K Ahuja; M Quinones; V Kostecki; R L Reddick; P C Melby; W A Kuziel; S S Ahuja
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  17 in total

1.  Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Authors:  Christopher H Logue; Aaron T Phillips; Eric C Mossel; Jeremy P Ledermann; Thomas Welte; Steve W Dow; Ken E Olson; Ann M Powers
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

2.  Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from Cystic fibrosis patients.

Authors:  Benjamin T Kopp; Basant A Abdulrahman; Arwa A Khweek; Surender B Kumar; Anwari Akhter; Richard Montione; Mia F Tazi; Kyle Caution; Karen McCoy; Amal O Amer
Journal:  Biochem Biophys Res Commun       Date:  2012-06-20       Impact factor: 3.575

3.  Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.

Authors:  Angela Henderson; Katie Propst; Ross Kedl; Steven Dow
Journal:  Vaccine       Date:  2011-05-19       Impact factor: 3.641

4.  A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists.

Authors:  Katie L Propst; Takehiko Mima; Kyoung-Hee Choi; Steven W Dow; Herbert P Schweizer
Journal:  Infect Immun       Date:  2010-04-19       Impact factor: 3.441

5.  MyD88-dependent recruitment of monocytes and dendritic cells required for protection from pulmonary Burkholderia mallei infection.

Authors:  Andrew Goodyear; Ryan Troyer; Helle Bielefeldt-Ohmann; Steven Dow
Journal:  Infect Immun       Date:  2011-10-24       Impact factor: 3.441

6.  MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells.

Authors:  Shun Li; Juan Lu; Yu Chen; Niya Xiong; Li Li; Jing Zhang; Hong Yang; Chunhui Wu; Hongjuan Zeng; Yiyao Liu
Journal:  Cell Mol Immunol       Date:  2016-03-21       Impact factor: 11.530

7.  Suppression of vaccine immunity by inflammatory monocytes.

Authors:  Leah A Mitchell; Angela J Henderson; Steven W Dow
Journal:  J Immunol       Date:  2012-11-07       Impact factor: 5.422

8.  Proteomic Analysis of Non-human Primate Peripheral Blood Mononuclear Cells During Burkholderia mallei Infection Reveals a Role of Ezrin in Glanders Pathogenesis.

Authors:  Chih-Yuan Chiang; Yang Zhong; Michael D Ward; Douglas J Lane; Tara Kenny; Raysa Rosario-Acevedo; Brett P Eaton; Sylvia R Treviño; Taylor B Chance; Meghan Hu; Patricia L Worsham; David M Waag; Richard T Moore; Lisa H Cazares; Christopher K Cote; Yingyao Zhou; Rekha G Panchal
Journal:  Front Microbiol       Date:  2021-04-22       Impact factor: 5.640

9.  A novel murine model of rhinoscleroma identifies Mikulicz cells, the disease signature, as IL-10 dependent derivatives of inflammatory monocytes.

Authors:  Cindy Fevre; Ana S Almeida; Solenne Taront; Thierry Pedron; Michel Huerre; Marie-Christine Prevost; Aurélie Kieusseian; Ana Cumano; Sylvain Brisse; Philippe J Sansonetti; Régis Tournebize
Journal:  EMBO Mol Med       Date:  2013-04       Impact factor: 12.137

Review 10.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.